Chemokines are essential mediators of normal leukocyte trafficking as well as of leukocyte recruitment during inflammation. We describe here a novel non-ELR CXC chemokine identified through sequence analysis of cDNAs derived from cytokine-activated primary human astrocytes. This novel chemokine, referred to as I-TAC (interferon-inducible T cell alpha chemoattractant), is regulated by interferon (IFN) and has potent chemoattractant activity for interleukin (IL)-2–activated T cells, but not for freshly isolated unstimulated T cells, neutrophils, or monocytes. I-TAC interacts selectively with CXCR3, which is the receptor for two other IFN-inducible chemokines, the IFN-γ–inducible 10-kD protein (IP-10) and IFN-γ– induced human monokine (HuMig), but with a significantly higher affinity. In addition, higher potency and efficacy of I-TAC over IP-10 and HuMig is demonstrated by transient mobilization of intracellular calcium as well as chemotactic migration in both activated T cells and transfected cell lines expressing CXCR3. Stimulation of astrocytes with IFN-γ and IL-1 together results in an ∼400,000-fold increase in I-TAC mRNA expression, whereas stimulating monocytes with either of the cytokines alone or in combination results in only a 100-fold increase in the level of I-TAC transcript. Moderate expression is also observed in pancreas, lung, thymus, and spleen. The high level of expression in IFN- and IL-1–stimulated astrocytes suggests that I-TAC could be a major chemoattractant for effector T cells involved in the pathophysiology of neuroinflammatory disorders, although I-TAC may also play a role in the migration of activated T cells during IFN-dominated immune responses.
Skip Nav Destination
Article navigation
15 June 1998
Article|
June 15 1998
Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3
Katherine E. Cole,
Katherine E. Cole
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Christine A. Strick,
Christine A. Strick
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Timothy J. Paradis,
Timothy J. Paradis
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Kevin T. Ogborne,
Kevin T. Ogborne
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Marcel Loetscher,
Marcel Loetscher
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Ronald P. Gladue,
Ronald P. Gladue
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Wen Lin,
Wen Lin
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
James G. Boyd,
James G. Boyd
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Bernhard Moser,
Bernhard Moser
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Douglas E. Wood,
Douglas E. Wood
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Barbara G. Sahagan,
Barbara G. Sahagan
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Kuldeep Neote
Kuldeep Neote
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Search for other works by this author on:
Katherine E. Cole
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Christine A. Strick
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Timothy J. Paradis
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Kevin T. Ogborne
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Marcel Loetscher
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Ronald P. Gladue
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Wen Lin
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
James G. Boyd
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Bernhard Moser
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Douglas E. Wood
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Barbara G. Sahagan
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Kuldeep Neote
From the *Department of Molecular Sciences and the ‡Department of Immunology, Central Research Division, Pfizer Inc., Groton, Connecticut 06340; and the §Theodor Kocher Institute, University of Bern, CH-300-ern-9, Switzerland
Address correspondence to Dr. Kuldeep Neote, Department of Molecular Science, Central Research Division, Pfizer Inc., Eastern Point Rd., Groton, CT 06340. Phone: 860-441-4081; Fax: 860-441-5719; E-mail: [email protected]
Received:
November 25 1997
Revision Received:
March 31 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 187 (12): 2009–2021.
Article history
Received:
November 25 1997
Revision Received:
March 31 1998
Citation
Katherine E. Cole, Christine A. Strick, Timothy J. Paradis, Kevin T. Ogborne, Marcel Loetscher, Ronald P. Gladue, Wen Lin, James G. Boyd, Bernhard Moser, Douglas E. Wood, Barbara G. Sahagan, Kuldeep Neote; Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 . J Exp Med 15 June 1998; 187 (12): 2009–2021. doi: https://doi.org/10.1084/jem.187.12.2009
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement